Drug Profile
Research programme: CXCR2 antagonists - Johnson & Johnson
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Indoles; Sulfonamides; Sulfonylureas
- Mechanism of Action Interleukin 8 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lung disorders; Respiratory tract disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA (PO)
- 20 Aug 2008 Preclinical trials in Lung disorders in USA (PO)